Literature DB >> 19048398

Correlation between osteopontin protein expression and histological grade of astrocytomas.

H Toy1, O Yavas, O Eren, M Genc, C Yavas.   

Abstract

Osteopontin is a ligand for the integrin proteins, which are cell surface receptors that mediate the physical and functional interactions between a cell and the extracellular matrix. The expression of osteopontin is reportedly increased in a number of transformed cell lines and tumor tissues. Furthermore, increased expression of osteopontin results in some infiltrative features of tumors. The aim of the study is to demonstrate that expression of osteopontin in human astrocytomas correlates with histological tumor grade. The expression of osteopontin in human astrocytomas was determined with immunohistochemistry. Median osteopontin expression levels were 1%, 7.5%, 60%, and 50% in grade I, II, III, and IV tumors, respectively. Osteopontin staining was significantly higher in high grade (grade III-IV) than low grade (grade I-II) tumors. These findings indicate that osteopontin immunoreactivity in human astrocytomas may correlate with the grade of a tumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19048398     DOI: 10.1007/s12253-008-9130-0

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  18 in total

Review 1.  Osteopontin.

Authors:  J Sodek; B Ganss; M D McKee
Journal:  Crit Rev Oral Biol Med       Date:  2000

Review 2.  Osteopontin expression and function: role in bone remodeling.

Authors:  D T Denhardt; M Noda
Journal:  J Cell Biochem Suppl       Date:  1998

3.  Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization.

Authors:  C Colin; N Baeza; C Bartoli; F Fina; N Eudes; I Nanni; P-M Martin; L Ouafik; D Figarella-Branger
Journal:  Oncogene       Date:  2006-05-04       Impact factor: 9.867

Review 4.  The functional and clinical roles of osteopontin in cancer and metastasis.

Authors:  K A Furger; R K Menon; A B Tuck; V H Bramwell; A F Chambers
Journal:  Curr Mol Med       Date:  2001-11       Impact factor: 2.222

5.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

6.  Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies.

Authors:  Domenico Coppola; Marianna Szabo; David Boulware; Patrick Muraca; Marwan Alsarraj; Ann F Chambers; Timothy J Yeatman
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

7.  Receptor-ligand interaction between CD44 and osteopontin (Eta-1).

Authors:  G F Weber; S Ashkar; M J Glimcher; H Cantor
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

8.  TPA-mediated regulation of osteopontin in human malignant glioma cells.

Authors:  M A Tucker; P L Chang; C W Prince; G Y Gillespie; T B Mapstone
Journal:  Anticancer Res       Date:  1998 Mar-Apr       Impact factor: 2.480

9.  Expression of osteopontin in human glioma. Its correlation with the malignancy.

Authors:  Y Saitoh; J Kuratsu; H Takeshima; S Yamamoto; Y Ushio
Journal:  Lab Invest       Date:  1995-01       Impact factor: 5.662

10.  Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.

Authors:  Philip S Rudland; Angela Platt-Higgins; Mohamed El-Tanani; Suzete De Silva Rudland; Roger Barraclough; John H R Winstanley; Rachel Howitt; Christopher R West
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  10 in total

1.  Definition of genetic events directing the development of distinct types of brain tumors from postnatal neural stem/progenitor cells.

Authors:  Falk Hertwig; Katharina Meyer; Sebastian Braun; Sara Ek; Rainer Spang; Cosima V Pfenninger; Isabella Artner; Gaëlle Prost; Xinbin Chen; Jaclyn A Biegel; Alexander R Judkins; Elisabet Englund; Ulrike A Nuber
Journal:  Cancer Res       Date:  2012-06-20       Impact factor: 12.701

2.  Studies on the role of osteopontin-1 in endometrial cancer cell lines.

Authors:  J C Hahne; S R Meyer; P Kranke; J Dietl; M Guckenberger; B Polat; A Hönig
Journal:  Strahlenther Onkol       Date:  2013-10-16       Impact factor: 3.621

3.  Contribution of tumor heterogeneity in a new animal model of CNS tumors.

Authors:  Fuyi Chen; Albert J Becker; Joseph J LoTurco
Journal:  Mol Cancer Res       Date:  2014-02-05       Impact factor: 5.852

4.  Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.

Authors:  Kuan-Yin Tseng; Min-Huey Chung; Huey-Kang Sytwu; Horng-Mo Lee; Kuan-Yu Chen; Chen Chang; Chih-Kung Lin; Che-Hung Yen; Jia-Hong Chen; Gu-Jiun Lin; Hsin-I Ma; Yi-Shian Yeh; Da-Tong Ju; Ming-Ying Liu; Dueng-Yuan Hueng
Journal:  J Neurooncol       Date:  2010-04-29       Impact factor: 4.130

5.  Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells.

Authors:  Wei Yan; Chunfa Qian; Peng Zhao; Junxia Zhang; Lei Shi; Jin Qian; Ning Liu; Zhen Fu; Chunshen Kang; Peiyu Pu; Yongping You
Journal:  Neuro Oncol       Date:  2010-02-08       Impact factor: 12.300

6.  Evaluation of osteopontin as a potential biomarker for central nervous system embryonal tumors.

Authors:  Yi-Peng Han; Chen-Kai Ma; Shen-Qi Wang; Atsushi Enomoto; Yang Zhao; Masahide Takahashi; Jie Ma
Journal:  J Neurooncol       Date:  2014-05-31       Impact factor: 4.130

7.  Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target.

Authors:  Jun Wei; Anantha Marisetty; Brett Schrand; Konrad Gabrusiewicz; Yuuri Hashimoto; Martina Ott; Zacharia Grami; Ling-Yuan Kong; Xiaoyang Ling; Hillary Caruso; Shouhao Zhou; Y Alan Wang; Gregory N Fuller; Jason Huse; Eli Gilboa; Nannan Kang; Xingxu Huang; Roel Verhaak; Shulin Li; Amy B Heimberger
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

8.  Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma.

Authors:  Qiu Yushi; Zhimin Li; Christina A Von Roemeling; Heike Doeppler; Laura A Marlow; Betty Y S Kim; Derek C Radisky; Peter Storz; John A Copland; Han W Tun
Journal:  Oncotarget       Date:  2016-05-31

9.  The embryonic type of SPP1 transcriptional regulation is re-activated in glioblastoma.

Authors:  Magdalena Kijewska; Marta Kocyk; Michal Kloss; Karolina Stepniak; Zbigniew Korwek; Renata Polakowska; Michal Dabrowski; Anna Gieryng; Bartosz Wojtas; Iwona A Ciechomska; Bozena Kaminska
Journal:  Oncotarget       Date:  2017-03-07

Review 10.  The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy.

Authors:  Erica C F Yeo; Michael P Brown; Tessa Gargett; Lisa M Ebert
Journal:  Cells       Date:  2021-03-09       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.